The specific role of ADAM17 in CRC, however, appears to be multifaceted as all three major ADAM17-regulated pathways (TNFα-, EGF-R- and IL-6-signaling) on different cell types are implicated in tumor progression. This evidence concerns the gene ADAM17 and neoplasm.